Hot Topic Roundtable

National Methadone Conference AMTA 2001

Tuesday, October 9th 2 P.M.


Administrative Detox: Necessary Use or Abuse

Joe Neuberger, Delaware NAMA

James DePasquale, Long Beach Patient Committee

This roundtable examined the practice of “administrative detoxification” from programs, and explored the conflicts between what programs often perceive as a necessary evil and patients often perceive as a source of anxiety and constant threat to their treatment.

Should administrative detox even be program policy if methadone is to be accepted truly as a medical procedure? The various issues will be presented in a statement format for attendees to discuss from the perspective of the patient and then the provider. The strategies that various advocacy groups have used to stop administrative detox policies and alternatives to administrative detox will be presented.

The workshop was designed so that attendees would come away with a greater appreciation and understanding of how patients perceive this as a threat to their very existence.

Bibliography

D’Aunno, T. and Vaughn, T.E. 8 January 1992. Variations in methadone treatment practices. Journal of the American Medical Association 267(2): 253-258.

Goldstein, A. 1994. Addiction. From Biology to Drug Policy. New York: W.H. Freeman & Company.

Kreek, M.J. 1992. The addict as patient. In: Lowinson, J.H., Ruiz, P., Millman, R.B. and Langrod, J.G. eds. Substance Abuse: A Comprehensive Textbook. Baltimore: Williams and Wilkens, pp 997-1011.

Click Here to download the abstract.


Workshop Evaluation

Presentation Category: Hot Topic Roundtable (1.5 Hours)
Primary Emphasis/Target Audience: Administrative: Management
Workshop Outcome-Oriented Education Objectives:

  1. To sensitize providers and professionals to the patients perception of forced administrative detox;
  2. Various alternatives to administrative detox will be presented; and
  3. Legal liability to programs that arbitrarily use administrative detox as a behavioral tool to control patients.



Return to AMTA 2001 Index

Similar Posts

  • Focus On

    Admin 02/26/2023

    Issues To Focus On Massachusetts Restores Methadone Funding Highlights from a compromise budget plan unveiled by House and Senate leaders on Thursday The $22.3 billion plan would: Restore Medicaid funding for 36,000 people under MassHealth Basic; Preserve a popular prescription drug coverage program for the elderly; Repeal the voter-approved Clean Elections law; Tighten the Quinn…

  • Links & Resources

    Admin 04/10/2021

    We Speak Methadone Join NAMA’s Bulletin Board and talk with other patients or just read what is happening around the world. SAMHSA Substance Abuse and Mental Health Services Administration. The federal agency that oversees mental health, substance abuse treatment and prevention agencies. CSAT Center for Substance Abuse Treatment. The federal agency under SAMHSA that oversees…

  • The National Methadone Conference-4

    Admin 01/16/2022

    American Association for the Treatment of Opioid Dependence Washington, D.C. ~ April 13-16, 2003 Hot Topic: Administrative Detox Facilitator: Joe Neuberger Delaware NAMA Bitch and Gripe.Com Administrative Detox is our subject. It is a policy whereby methadone patients in treatment are banished from their programs for the umbrella term of “non-compliance.” Now we’re not talking…

  • NAMA Organizational Meeting Monday, October 8th, 7 P.M.

    Admin 09/24/2022

    NAMA Organizational Meeting Monday, October 8th, 7 P.M. Chairs Jo Sotheran, NAMA Board of Directors (Treasurer) Joycelyn Woods, NAMA Board of Directors (President) As meeting starts Joycelyn Woods looks on over the shoulders of Tony Scro (NAMA Grievance Coordinator), James DePasquale (Long Island NAMA) and Donna Schoen (LIJ Patient Committee). Jo Sotheran introduces the reasons…

  • Page 4098 Federal Register

    Admin 08/28/2021

     Vol. 66, No. 11 / Wednesday, January 17, 2001 / Rules and Regulations (i)                 Unsupervised or take-home use.   To limit the potential for diversion of opioid agonist treatment medications to the illicit market, opioid agonist treatment medications dispensed to patients for unsupervised use shall be subject to the following requirements.   (1)   Any patient…